The Atossa Therapeutics (NASDAQ:ATOS) stock has been in sharp focus among investors in recent weeks and it continued this morning, as the stock soared by another 25% to take its gains to 250% over the past five weeks.
This morning the clinical stage biopharmaceutical stock jumped after the company announced that it is all set to hold a webinar on June 9, 2021. At this webinar, Atossa is going to announce the results from the Phase 2 study of its product Endofixen.
The product is meant as a pre-surgery medicine for patients suffering from breast cancer. Some of the company’s top executives are going to be in attendance at this webinar and there is also going to be a discussion on the data from the results.
Those who want to join the ZOOM call for the webinar need to visit the Tribe Public LLC website. All those who are registered to participate will be able to email their questions as well.
Market Action
As of 11:07, ATOS stock has soared by 24.68% to $5.76 and made a new 52-week high of $6.35. The stock has seen huge volume with more than 31.4 million shares already traded, well above its 30-day average volume of 11.54 million.
 Stock Hits Multi-Year High: How Far Will It Go?){kind=link}